Eli Lilly and Company's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Posted:
FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
Capital planning in healthcare is not merely an administrative obligation—it is a strategic discipline that shapes clinical capabilities, operational resilience and financial health.
Recognising and addressing common planning mistakes is essential to sustaining high-quality, efficient care in an increasingly complex…
The US Food and Drug Administration has approved the first eye drop that could allow users to ditch their bifocals—or at least rely on them far less often. Developed by the pharmaceutical company LENZ, VIZZ is an aceclidine ophthalmic treatment in the form of…
Attendees
Sponsors and Exhibitors
Contact us